The global Psoriasis Therapeutics Market Study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Drug Class (TNF-alpha Inhibitors, Interleukin Inhibitors), By Type (Plaque Psoriasis, Psoriatic Arthritis, Others), By Route of Administration (Oral, Parenteral, Topical), By Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Providers, Others).
Psoriasis is a chronic inflammatory skin condition characterized by erythematous plaques, silvery scales, and pruritus, affecting millions of individuals worldwide and posing significant challenges in disease management and quality of life. In 2024, the Psoriasis Therapeutics Market continues to expand rapidly, driven by advances in understanding disease pathogenesis, the introduction of biologic agents targeting specific immune pathways, and the development of novel small molecule therapies. Key trends include the adoption of combination therapy approaches to maximize treatment efficacy and durability, the integration of patient-centric care models emphasizing holistic disease management and lifestyle interventions, and the emergence of biosimilars offering cost-effective alternatives to branded biologics. Moreover, ongoing research into the role of the microbiome, immune dysregulation, and genetic predisposition in psoriasis susceptibility is driving innovation and shaping future treatment paradigms. With a robust pipeline of next-generation therapeutics and a growing emphasis on personalized medicine, the psoriasis therapeutics market holds promise for improved outcomes and enhanced quality of life for patients living with this chronic inflammatory disorder.
The global Psoriasis Therapeutics Industry is highly competitive with a large number of companies focusing on niche market segments. Amidst intense competitive conditions, Psoriasis Therapeutics Companies are investing in new product launches and strengthening distribution channels. Key companies operating in the Psoriasis Therapeutics Industry include- Abbvie Inc, Amgen Inc, Bausch Health Companies Inc, Eli Lilly and Company, Johnson and Johnson, LEO Pharma, Novan Inc, Novartis AG, Pfizer Inc, Viatris Inc.
In the realm of psoriasis therapeutics, a significant trend is the shift towards biologic therapies as the preferred treatment option for moderate to severe psoriasis. Biologic drugs, such as tumor necrosis factor-alpha (TNF-alpha) inhibitors, interleukin (IL)-17 inhibitors, and IL-23 inhibitors, have revolutionized the management of psoriasis by targeting specific immune pathways involved in the disease process. These biologics offer superior efficacy and safety profiles compared to traditional systemic therapies such as methotrexate and cyclosporine, making them increasingly favored by healthcare providers and patients alike. This trend towards biologic therapies reflects the growing understanding of the immunopathogenesis of psoriasis and the need for targeted treatments that address the underlying inflammatory pathways driving the disease.
The growing prevalence and impact of psoriasis serve as significant market drivers for psoriasis therapeutics. Psoriasis is a chronic inflammatory skin condition affecting millions of people worldwide, with significant physical, emotional, and psychosocial burdens on patients' quality of life. As awareness of psoriasis increases and diagnostic rates improve, there's a growing demand for effective treatments that can alleviate symptoms, reduce disease severity, and improve long-term outcomes. The availability of biologic therapies with targeted mechanisms of action has transformed the treatment landscape for psoriasis, offering hope for improved symptom control and disease management for patients with moderate to severe disease.
A promising opportunity in the psoriasis therapeutics market lies in the advancement of personalized treatment approaches tailored to individual patient needs and disease characteristics. Psoriasis is a heterogeneous disease with varying clinical presentations, disease severity, and treatment responses among patients. Personalized treatment strategies that consider factors such as genetic predisposition, comorbidities, and biomarker profiles offer the potential to optimize treatment outcomes and improve patient satisfaction. Additionally, the integration of patient-reported outcomes and digital health technologies such as telemedicine and mobile applications can enhance treatment adherence, monitoring, and patient engagement in psoriasis care. Investing in the development and implementation of personalized treatment approaches presents a strategic opportunity for pharmaceutical companies to differentiate their products and address the diverse needs of patients with psoriasis, ultimately improving treatment outcomes and quality of life.
Among the various drug classes for psoriasis therapeutics, the segment of Interleukin Inhibitors, particularly for treating Psoriatic Arthritis, is experiencing the fastest growth. Psoriatic Arthritis is a chronic inflammatory condition that affects both the skin and joints, causing pain, swelling, and stiffness. Interleukin Inhibitors, a relatively newer class of biologic drugs, target specific cytokines involved in the inflammatory process underlying psoriatic arthritis. These medications have shown remarkable efficacy in reducing joint inflammation and slowing down disease progression, offering significant relief to patients suffering from this debilitating condition. The increasing recognition of psoriatic arthritis as a distinct entity within the spectrum of psoriasis-related disorders, coupled with advancements in biologic therapies targeting interleukins, has propelled the growth of this segment. As a result, pharmaceutical companies are investing heavily in the development and commercialization of interleukin inhibitors, driving expansion in the market for psoriatic arthritis therapeutics. This growth trend is expected to continue as more patients seek effective and targeted treatments for their psoriatic arthritis symptoms.
By Drug Class
TNF-alpha Inhibitors
Interleukin Inhibitors
By Type
Plaque Psoriasis
Psoriatic Arthritis
Others
By Route of Administration
Oral
Parenteral
Topical
By Distribution Channel
Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Providers
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
Abbvie Inc
Amgen Inc
Bausch Health Companies Inc
Eli Lilly and Company
Johnson and Johnson
LEO Pharma
Novan Inc
Novartis AG
Pfizer Inc
Viatris Inc
* List not Exhaustive
• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Psoriasis Therapeutics Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Psoriasis Therapeutics Industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.
TABLE OF CONTENTS
1 Introduction to 2024 Psoriasis Therapeutics Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain
2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations
3 Executive Summary
3.1 Global Psoriasis Therapeutics Market Size Outlook, $ Million, 2021 to 2030
3.2 Psoriasis Therapeutics Market Outlook by Type, $ Million, 2021 to 2030
3.3 Psoriasis Therapeutics Market Outlook by Product, $ Million, 2021 to 2030
3.4 Psoriasis Therapeutics Market Outlook by Application, $ Million, 2021 to 2030
3.5 Psoriasis Therapeutics Market Outlook by Key Countries, $ Million, 2021 to 2030
4 Market Dynamics
4.1 Key Driving Forces of Psoriasis Therapeutics Industry
4.2 Key Market Trends in Psoriasis Therapeutics Industry
4.3 Potential Opportunities in Psoriasis Therapeutics Industry
4.4 Key Challenges in Psoriasis Therapeutics Industry
5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Psoriasis Therapeutics Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook
6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts
7 Global Psoriasis Therapeutics Market Outlook by Segments
7.1 Psoriasis Therapeutics Market Outlook by Segments, $ Million, 2021- 2030
By Drug Class
TNF-alpha Inhibitors
Interleukin Inhibitors
By Type
Plaque Psoriasis
Psoriatic Arthritis
Others
By Route of Administration
Oral
Parenteral
Topical
By Distribution Channel
Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Providers
Others
8 North America Psoriasis Therapeutics Market Analysis and Outlook To 2030
8.1 Introduction to North America Psoriasis Therapeutics Markets in 2024
8.2 North America Psoriasis Therapeutics Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Psoriasis Therapeutics Market size Outlook by Segments, 2021-2030
By Drug Class
TNF-alpha Inhibitors
Interleukin Inhibitors
By Type
Plaque Psoriasis
Psoriatic Arthritis
Others
By Route of Administration
Oral
Parenteral
Topical
By Distribution Channel
Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Providers
Others
9 Europe Psoriasis Therapeutics Market Analysis and Outlook To 2030
9.1 Introduction to Europe Psoriasis Therapeutics Markets in 2024
9.2 Europe Psoriasis Therapeutics Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Psoriasis Therapeutics Market Size Outlook by Segments, 2021-2030
By Drug Class
TNF-alpha Inhibitors
Interleukin Inhibitors
By Type
Plaque Psoriasis
Psoriatic Arthritis
Others
By Route of Administration
Oral
Parenteral
Topical
By Distribution Channel
Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Providers
Others
10 Asia Pacific Psoriasis Therapeutics Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Psoriasis Therapeutics Markets in 2024
10.2 Asia Pacific Psoriasis Therapeutics Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Psoriasis Therapeutics Market size Outlook by Segments, 2021-2030
By Drug Class
TNF-alpha Inhibitors
Interleukin Inhibitors
By Type
Plaque Psoriasis
Psoriatic Arthritis
Others
By Route of Administration
Oral
Parenteral
Topical
By Distribution Channel
Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Providers
Others
11 South America Psoriasis Therapeutics Market Analysis and Outlook To 2030
11.1 Introduction to South America Psoriasis Therapeutics Markets in 2024
11.2 South America Psoriasis Therapeutics Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Psoriasis Therapeutics Market size Outlook by Segments, 2021-2030
By Drug Class
TNF-alpha Inhibitors
Interleukin Inhibitors
By Type
Plaque Psoriasis
Psoriatic Arthritis
Others
By Route of Administration
Oral
Parenteral
Topical
By Distribution Channel
Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Providers
Others
12 Middle East and Africa Psoriasis Therapeutics Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Psoriasis Therapeutics Markets in 2024
12.2 Middle East and Africa Psoriasis Therapeutics Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Psoriasis Therapeutics Market size Outlook by Segments, 2021-2030
By Drug Class
TNF-alpha Inhibitors
Interleukin Inhibitors
By Type
Plaque Psoriasis
Psoriatic Arthritis
Others
By Route of Administration
Oral
Parenteral
Topical
By Distribution Channel
Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Providers
Others
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Abbvie Inc
Amgen Inc
Bausch Health Companies Inc
Eli Lilly and Company
Johnson and Johnson
LEO Pharma
Novan Inc
Novartis AG
Pfizer Inc
Viatris Inc
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise
By Drug Class
TNF-alpha Inhibitors
Interleukin Inhibitors
By Type
Plaque Psoriasis
Psoriatic Arthritis
Others
By Route of Administration
Oral
Parenteral
Topical
By Distribution Channel
Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Providers
Others
The global Psoriasis Therapeutics Market is one of the lucrative growth markets, poised to register a 7.2% growth (CAGR) between 2024 and 2030.
Emerging Markets across Asia Pacific, Europe, and Americas present robust growth prospects.
Abbvie Inc, Amgen Inc, Bausch Health Companies Inc, Eli Lilly and Company, Johnson and Johnson, LEO Pharma, Novan Inc, Novartis AG, Pfizer Inc, Viatris Inc
Base Year- 2023; Estimated Year- 2024; Historic Period- 2018-2023; Forecast period- 2024 to 2030; Currency: USD; Volume